Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07102381 | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer(EmpowHER 208) | recruiting | Phase 2 | 125 | Jazz PharmaceuticalsINDUSTRY | 3 | Aug 25, 2026 | clinicaltrials |
| NCT05501704 | ETHAN - ET for Male BC | recruiting | Phase 2 | 60 | Jose Pablo LeoneOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06084481 |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 |
| recruiting |
| Phase 1 |
| 325 |
| AbbVieINDUSTRY |
| 8 |
| Aug 24, 2026 |
| clinicaltrials |
| NCT07743190 | A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)(NeoTILs) | recruiting | Phase 2 | 55 | Medical University of South CarolinaOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06441890 | BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer(BRE-10) | recruiting | Phase 2 | 28 | University of Illinois at ChicagoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06536881 | Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming(GAMMER) | recruiting | N/A | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06738654 | Application of Single-Port Robot-Assisted Breast-Conserving Surgery Via Axillary Approach for Breast Cancer.(单孔机器人-SPR) | recruiting | N/A | 64 | Xu YanOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07067138 | A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) | recruiting | N/A | 175 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07321015 | A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance(Fzp-MA-TNBC) | recruiting | Phase 2 | 72 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05557877 | Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer | recruiting | Phase 2 | 60 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07191717 | Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial | recruiting | Phase 2 | 42 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07459673 | HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission | recruiting | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03604315 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | recruiting | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04893109 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | recruiting | Phase 2 | 500 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05787834 | Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer | recruiting | N/A | 130 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05919108 | Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | recruiting | Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT06218303 | Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | recruiting | Phase 1 | 50 | Finn, Olivera, PhDOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | recruiting | Phase 1 | 150 | Normunity AccelCo, Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07544056 | A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 / Phase 3 | 446 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04332588 | Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI | recruiting | Phase 1 | 25 | University of Alabama at BirminghamOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04861077 | Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) | recruiting | Early Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT06358573 | Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK | recruiting | Phase 2 | 61 | Swiss Cancer InstituteOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06500481 | Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | recruiting | Phase 3 | 115 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06869629 | Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer(SENOMAC-ULTRA) | recruiting | N/A | 1,380 | Karolinska InstitutetOTHER | 3 | Aug 17, 2026 | clinicaltrials |
| NCT07341867 | Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | recruiting | Phase 1 | 90 | Andrew Hantel, MDOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07768436 | A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer | recruiting | Phase 2 | 76 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04797299 | Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)(ELISA) | recruiting | — | 526 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06518057 | Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer | recruiting | Phase 2 | 22 | University of WashingtonOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07699991 | A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors | recruiting | N/A | 330 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07737951 | Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia | recruiting | N/A | 40 | Thomas Jefferson UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07764796 | Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya | recruiting | N/A | 800 | Emory UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT07762885 | Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery | recruiting | Phase 3 | 636 | Fudan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07762924 | Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery | recruiting | Phase 2 | 234 | Fudan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04768426 | Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | recruiting | Phase 2 | 40 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06525766 | Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 35 | Mayo ClinicOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07752238 | Diagnostic Prediction Model for De Novo Metastatic Breast Cancer | recruiting | — | 925 | Markusovszky University Teaching Hospital os County VasOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03408353 | Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study | recruiting | — | 10,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT05111561 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07044310 | 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss | recruiting | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07482384 | Supporting Health Including Endocrine Treatment for Long Duration(SHIELD) | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07741968 | A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer | recruiting | N/A | 126 | City of Hope Medical CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06176261 | DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | recruiting | Phase 2 | 58 | Nancy Lin, MDOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06439693 | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 25, 2026source: clinicaltrials